FIELD: chemistry.
SUBSTANCE: invention relates to biotechnology and specifically to obtaining glucagon analogues and can be used in medicine. The peptide amino acid sequence includes a negatively charged amino acid at position 28 and a negatively charged amino acid at position 29 or 30 of the native glucagon sequence (SEQ ID NO: 1). The amino acid sequence can also include up to 7 additional amino acid modifications with respect to SEQ ID NO: 1, which enable the glucagon peptide to retain glucagon activity and improved solubility or stability. The obtained peptide is used to treat hypoglycaemia and for temporary paralysis of the intestinal tract.
EFFECT: invention enables to obtain a glucagon peptide with improved solubility or stability with respect to the native glucagon.
15 cl, 10 dwg, 4 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GLUCAGON ANALOGUES, POSSESSING HIGHER SOLUBILITY AND STABILITY IN BUFFERS WITH PHYSIOLOGICAL Ph VALUES | 2009 |
|
RU2560254C2 |
| AMIDE-BASED PRODRUGS OF GLUCAGON SUPERFAMILY PEPTIDES | 2009 |
|
RU2550696C2 |
| INSULIN-INCRETIN CONJUGATES | 2014 |
|
RU2678134C2 |
| GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | 2011 |
|
RU2604067C2 |
| PEPTIDE PRO-DRUGS OF AMIDE GLUCAGON SUPERFAMILY | 2011 |
|
RU2580317C2 |
| CONJUGATE CONTAINING OXINTOMODULIN AND IMMUNOGLOBULIN FRAGMENT, AND ITS APPLICATION | 2012 |
|
RU2733544C2 |
| CONJUGATE, CONTAINING OXYNTOMODULIN AND FRAGMENT OF IMMUNOGLOBULIN, AND USE THEREOF | 2012 |
|
RU2607365C2 |
| NEW METHOD FOR OBTAINING LONG-ACTING DRUG CONJUGATE BY PRODUCING INTERMEDIATE | 2019 |
|
RU2805873C2 |
| OXYINTOMODULINE | 2009 |
|
RU2542362C2 |
| DIPEPTIDE LINKED MEDICINAL AGENTS | 2009 |
|
RU2578591C2 |
